ArticleScientific reports2025
In silico and in vitro evaluation of drug-like properties and anticancer potential of novel 5-fluorouracil derivatives.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The development of more effective and safer anticancer agents remains a critical focus in cancer therapy. While biologics are gaining attention, small molecules continue to play a significant role due to their versatility and cost-effectiveness. This study investigates the potential of synthesized 5-fluorouracil derivatives to improve its drug-like properties, as well as anticancer activity in human lung cancer cells. Among the synthesized compounds, two (2c and 3a) demonstrated greater cytotoxicity and selectivity toward A549 lung cancer cells compared to 5-FU. These derivatives did not induce oxidative stress but instead affected antioxidant enzyme activity, suggesting interference with cellular metabolism. Additionally, these derivatives shifted cells toward hypodiploidy, suggesting the presence of apoptotic cells, while 5-FU significantly increased A549 cell ploidy, a trait linked to cancer progression and treatment resistance. In silico predictions revealed improved pharmacokinetic properties for the 2c derivative and a low probability of hepatotoxicity or neurotoxicity compared to 5-FU. These findings suggest that 2c and 3a derivatives warrant further research as potentially safer and more effective alternatives to 5-FU.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.